RecruitingPhase 2NCT07421167
Blood
Immune Thrombocytopenic Purpura
Also known as ITP, idiopathic thrombocytopenic purpura, immune thrombocytopenia
Immune thrombocytopenic purpura is an acquired autoimmune disorder in which autoantibodies directed against platelet surface glycoproteins (primarily GPIIb/IIIa and GPIb/IX) accelerate platelet destruction by the reticuloendothelial system
ORPHA:3002 ↗Prevalence 5-10 per 100,000Onset Any age; acute form common in children after viral illness; chronic form more common in adultsAcquired autoimmune
101
studies recruiting now
as of 7 Sept 2026
563
studies registered in total
as of 7 Sept 2026
15
countries with a recruiting site
as of 7 Sept 2026
26 Aug 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 1NCT07083960
OM336 in Autoimmune Cytopenias
RecruitingPhase 4NCT07788456
Multi-target Drugs Sequential Combination Therapy in Adults Patients With Newly Diagnosed Primary Immune Thrombocytopenia
RecruitingNCT07786077
A Study of Patients' Preferences for Primary Immune Thrombocytopenia Treatment
RecruitingPhase 3NCT06948318
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 101 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Immune Thrombocytopenic Purpura study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
Registry: ITP World Impact Survey (IWISh) · Join ↗. Registries connect patients to researchers and often hear about trials first.
About Immune Thrombocytopenic Purpura
Immune thrombocytopenic purpura is an acquired autoimmune disorder in which autoantibodies directed against platelet surface glycoproteins (primarily GPIIb/IIIa and GPIb/IX) accelerate platelet destruction by the reticuloendothelial system and impair megakaryocyte platelet production in the bone marrow. It is classified as newly diagnosed (less than 3 months), persistent (3-12 months), or chronic (greater than 12 months), with the chronic form predominantly affecting adult women. Treatment options include corticosteroids, intravenous immunoglobulin, thrombopoietin receptor agonists, rituximab, and splenectomy, reflecting its heterogeneous pathophysiology.
Common clinical features
Thrombocytopenia with platelet count typically below 100,000/uLEasy bruising and purpuraPetechiae particularly on the lower extremitiesMucosal bleeding including gingival and epistaxisMenorrhagia in women of childbearing ageFatigue independent of anemiaRisk of intracranial hemorrhage at very low platelet countsGenerally normal white blood cell and red blood cell counts
From Orphanet’s phenotype annotations (CC BY 4.0). Not a complete list.
Treatments being studied
16 approved treatments and 52 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Approved: Cortisone Acetate (Cortate)Approved: Dexamethasone (Aeroseb-dex)Approved: FostamatinibApproved: Prednisone (Cortan)Approved: Human Immunoglobulin G (Flebogamma dif (previously flebogammadif))Approved: Gma-161Approved: Eltrombopag Olamine (Promacta)Approved: Romiplostim (Nplate)Approved: Esomeprazole Magnesium (Emozul)Approved: RilzabrutinibApproved: ValzifloceptApproved: Vonoprazan Fumarate (Voquezna)Approved: Fostamatinib Disodium (Tavalisse)Approved: Eltrombopag (Revolade)Approved: Dexamethasone Sodium Phosphate (Ak-dex)Approved: Eltrombopag Choline (Alvaiz)
Phase 3Efgartigimod Alfa (Efgartigimod alfa component of vyvgart hytrulo)
Phase 3Prednisolone (Cortalone)
Phase 3Decitabine (Dacogen)
Phase 3Oseltamivir
Phase 3Bortezomib
Phase 3Hetrombopag Olamine
Phase 3Caffeic Acid
Phase 3Cyclosporine (Capimune)
+ 44 more in development
Before you apply
Things trial teams commonly ask about for Immune Thrombocytopenic Purpura. Not eligibility rules; those are set by each study.
- Document your ITP phase (newly diagnosed, persistent, or chronic), as most interventional trials target chronic ITP with at least 12 months of disease; bring platelet count trends over time.
- Prior treatment history including corticosteroids, IVIG, anti-D immunoglobulin, rituximab, splenectomy, and thrombopoietin receptor agonist (TPO-RA) use and response is critical for eligibility in second-line and salvage therapy trials.
- Pregnancy status, concurrent autoimmune conditions (SLE, antiphospholipid syndrome), and secondary ITP causes must be excluded for most primary ITP trial enrollment.
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).